Medicare cancer-drug payment shift may cut access elsewhere

What it does

This bill requires Medicare to pay separately for expensive cancer drugs administered in hospital outpatient settings, rather than bundling their cost into a flat payment for the entire visit. Starting in 2026, cancer drugs costing $350 or more per day are eligible for separate reimbursement based on their actual acquisition cost (average sales price, wholesale cost, or hospital claims data). The bill is budget-neutral—Medicare adjusts other payments to offset the cost of these separate payments.

Why we flagged it

The bill's core mechanism is a reimbursement policy change—carving out separate payment for high-cost cancer drugs from bundled outpatient payments. This is a regulatory/payment reform, not a subsidy or deregulation, though it redistributes Medicare dollars within the system.

What the text implies

• Budget neutrality requirement means Medicare must reduce payments elsewhere in the outpatient system to fund separate cancer-drug payments, potentially affecting access to non-cancer treatments or increasing beneficiary cost-sharing.
• The $350/day threshold and annual adjustment mechanism create a moving target; drugs crossing the threshold in future years will suddenly shift to separate payment, creating unpredictability for hospital billing and potentially incentivizing cost inflation.

The full analysis lists 4 implications of this text.

Who stands to gain

pharmaceutical manufacturers (Johnson & Johnson, Bristol Myers Squibb, others) — higher reimbursemen; hospitals with high-volume oncology programs — improved reimbursement for expensive cancer drug admi; specialty pharmacy networks — potential increased volume and margin from separate-payment billing